Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 26c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.49, $0.26 better than the analyst estimate of $3.23. Revenue for the quarter came in at $500.48 million versus the consensus estimate of $469.62 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $13.09. Jazz Pharmaceuticals sees FY2018 revenue of $1.88-1.93 million, versus the consensus of $1.9 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• KB Home (KBH) PT Lowered to $50 at RBC Capital